What to expect if planning to try Gilenya
By Cherie C. Binns RN BS MSCN
If you have been waiting for one of the new oral medications for MS to be FDA approved, you are likely excited to see that Fingolimod (marketed under the name Gilenya) was approved for patients with relapsing forms of MS on September 21. Many people with MS (PWMS) have been awaiting this news hoping to be able to move away from the injectable medications. The actual medication, however, will not be available for prescription for several more weeks.
Continue reading this information by clicking here
"Providing You with 'MS Views and News', is what we do"
Keep Informed and up-to-date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: 'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
2 comments:
New prescribing information received yesterday indicates that one must wait a full month after receiving the VZV (chickenpox vaccine) if titers of antibodies are low, prior to starting Gilenya. It also states that no vaccines may be received while on Gilenya or for two months after stopping the medication.
Persons with diabetes are more prone to macular edema (one of the potential side effects) and might not be considered for this drug based on this condition being present. Vision loss with macular edema is less treatable than optic neuritis and may cause more permanent loss of vision.
I just heard (on another MS site) that the cost of Novartis' Gilenya will be $48,000/year or $4000/month...more than any of the injectables or tysabri. I do not know this to be factual.
Post a Comment